Principia Biopharma Inc. (PRNB) financial statements (2020 and earlier)

Company profile

Business Address 220 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments316177
Cash and cash equivalents4034
Short-term investments276142
Restricted cash and investments 0
Prepaid expense32
Other undisclosed current assets12
Total current assets:320181
Noncurrent Assets
Property, plant and equipment102
Long-term investments and receivables524
Long-term investments524
Restricted cash and investments11
Other noncurrent assets09
Total noncurrent assets:6315
TOTAL ASSETS:383196
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities910
Accounts payable24
Accrued liabilities11
Employee-related liabilities74
Deferred rent credit1 
Other undisclosed current liabilities67
Total current liabilities:1617
Noncurrent Liabilities
Liabilities, other than long-term debt89
Deferred rent credit89
Total noncurrent liabilities:89
Total liabilities:2426
Stockholders' equity
Stockholders' equity attributable to parent359170
Common stock00
Additional paid in capital545302
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(186)(132)
Total stockholders' equity:359170
TOTAL LIABILITIES AND EQUITY:383196

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:3569
Operating expenses(94)(52)
Operating income (loss):(59)17
Nonoperating income51
Investment income, nonoperating52
Other nonoperating expense (1)
Income (loss) from continuing operations before income taxes:(54)18
Income tax expense (0)
Income (loss) before gain (loss) on sale of properties:(54)18
Other undisclosed net income 0
Net income (loss) attributable to parent:(54)18
Undistributed earnings (loss) allocated to participating securities, basic (13)
Net income (loss) available to common stockholders, diluted:(54)5

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net income (loss):(54)18
Comprehensive income (loss):(54)18
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive income (loss), net of tax, attributable to parent:(54)18

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: